Press Release: Amgen : IMDELLTRA DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment...
Read full article »
Amgen is a California-based multinational biopharmaceutical company that develops human therapeutics for the treatment of diseases including cancer and cardiovascular.
Read more